Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Fig. 1

ACR responses in PsA patients receiving apremilast 30 mg up to 260 weeks. Data as observed. The analysis includes all patient data, including the placebo-controlled phase, regardless of when the patients started taking apremilast (baseline, week 16, or week 24). The proportions of psoriatic arthritis (PsA) patients achieving ACR20, ACR50, or ACR70 responses at study visits up to week 260 are shown. Error bars represent 95% confidence interval (CI). n represents the number of patients with data available at that time point

Back to article page